GLP-1 Agonist Therapy Center

Promising results from IDegLira and the DUAL I trial…. Novo Nordisk’s new drug IDegLira is a fixed-ratio combination of insulin degludec and the glucagonlike perptide-1 (GLP-1) agonist liraglutide. It combines the effects of insulin degludec and liraglutide in a once daily injection. In the Dual Action of Liraglutide and Insulin …

A new combination of long-acting insulin plus a GLP-1 compound is in phase 3 trials and the results are outstanding….

According to the European Medicines Agency’s Committee for Medicinal Products for Human Use, current data linking glucagon-like-peptide-1 (GLP-1) agonists to adverse pancreatic events are not adequate….

A recent meta-analysis has shown that patients with type 2 diabetes (T2DM) may not have impaired secretion of glucagon-like peptide-1 (GLP-1)…. The study conducted by researchers at Gentofte Hospital at the University of Copenhagen, revealed that T2DM patients had similar levels of GLP-1 secretion as controls after an oral glucose …

Five studies show positive results for new GLP-1 drug dulaglutide…. Eli Lilly and Company announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. Primary efficacy endpoints of …

One more GLP-1 agonist gets approved in Europe…. The European Commission has granted approval of lixisenatide (Lyxumia, Sanofi) for the treatment of adults with type 2 diabetes. The drug, a once-daily glucagon-like peptide 1 (GLP-1) agonist, is indicated to achieve glycemic control in combination with oral glucose-lowering products and/or basal …

Preliminary evidence from a clinical trial suggests that treatment with GLP-1 receptor agonists was associated with…. Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report …

Are patients with a higher baseline A1C more likely to have a better glycemic response to GLP-1 treatments?… The retrospective observational cohort study was done to determine predictors of glycemic response to exenatide and to assess change in glycosylated hemoglobin (A1C) and whether a correlation exists between weight loss and …

Amanda Zell, PharmD Candidate, Mercer University College of Pharmacy Glucagon-like peptide-1 (GLP-1) is part of a family of peptide hormones known as incretins. Incretins, such as GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), are secreted by entero-endocrine cells of the gastrointestinal tract to stimulate glucose-dependent insulin secretion and beta-cell proliferation. GLP-1 receptor …

Dr. Edelman gives us his thoughts on how the GLP-1 analogs have changed the way we practice, and why he thinks the GLP-1 drugs are the single most important advance for type 2 patients in recent years. He says that GLP-1’s are not being prescribed as much as they should be probably …